High Lipoprotein(a) Predicts Cardiac Events in DM With PCI
High Lp(a) independent predictor of cardiac death, acute coronary syndrome in multivariate analysis
WEDNESDAY, Dec. 7, 2016 (HealthDay News) -- For patients with diabetes mellitus (DM) undergoing percutaneous coronary intervention (PCI), high lipoprotein(a) (Lp[a]) levels are associated with advanced cardiac events, according to a study published in the Dec. 15 issue of The American Journal of Cardiology.
Hirokazu Konishi, M.D., Ph.D., from Juntendo University Shizuoka Hospital in Japan, and colleagues examined the role of Lp(a) in patients with DM who underwent PCI. Data were included for 1,136 eligible patients, who were divided into two groups based on the median of Lp(a) levels (high Lp[a], 575 patients and low Lp[a], 561 patients). Patients were followed for a median of 4.7 years.
The researchers found that the event rate of all-cause death was not significantly different between the groups. The high Lp(a) group had significantly higher cumulative incidence of cardiac death and acute coronary syndrome than the low Lp(a) group. High Lp(a) was an independent predictor of cardiac death and acute coronary syndrome in multivariable analysis (hazard ratio, 1.2).
"In conclusion, a high Lp(a) value could be associated with advanced cardiac events after PCI for patients with DM," the authors write.